Allarity Therapeutics Files 8-K Report

TL;DR

Allarity Therapeutics filed an 8-K on Jan 30, 2025, reporting 'Other Events'.

AI Summary

On January 30, 2025, Allarity Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and does not detail specific financial transactions or significant business developments within the provided text. The report confirms the company's identity, incorporation in Delaware, and principal executive offices in Boston, MA.

Why It Matters

This 8-K filing serves as an official notification to the SEC and the public about significant events or changes related to Allarity Therapeutics, Inc.

Risk Assessment

Risk Level: low — The filing is a routine disclosure and does not contain information indicating immediate financial or operational risk.

Key Players & Entities

• Allarity Therapeutics, Inc. (company) — Registrant
• January 30, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• Boston, MA (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock , par value $0.0001 per share ALLR The Nasdaq Stock Mark
• $2,500,000 — ld also pay a one-time civil penalty of $2,500,000 and the Company would agree to fully co
• $3.5 million — insurance coverage in place once up to $3.5 million has been incurred. Through the end of 2
• $1.8 million — d in cash an aggregate of approximately $1.8 million in fees and expenses for the representa

Filing Documents

• allr20250117_8k.htm (8-K) — 29KB
• 0001437749-25-002184.txt ( ) — 166KB
• allr-20250130.xsd (EX-101.SCH) — 3KB
• allr-20250130_def.xml (EX-101.DEF) — 12KB
• allr-20250130_lab.xml (EX-101.LAB) — 16KB
• allr-20250130_pre.xml (EX-101.PRE) — 12KB
• allr20250117_8k_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. Settlement in Principle As previously disclosed, Allarity Therapeutics, Inc. (the "Company") has been the subject of an investigation (the "Investigation") by the Securities and Exchange Commission (the "SEC") which relates to the Company's disclosures regarding meetings with the United States Food and Drug Administration (the "FDA") regarding the Company's New Drug Application ("NDA") for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021. The Company has reached an agreement in principle with the SEC staff to resolve the Investigation with respect to the Company. Under the terms of the settlement, the Company would consent, without admitting or denying the SEC's findings, to the entry of an administrative cease-and-desist order. This order would resolve the SEC's investigation with findings of violations of non-scienter based charges under Sections 17(a)(2) and (3) of the Securities Act of 1933, and Section 13(a) of the Securities Exchange Act of 1934 and Rules 12b-20, 13a-11, and 13a-13 under the Exchange Act. As part of the settlement, the Company would also pay a one-time civil penalty of $2,500,000 and the Company would agree to fully cooperate with the SEC in any litigation going forward. This agreement in principle with the SEC staff remains subject to mutual agreement on the final language of the settlement documents and approval by the SEC. Accordingly, the Company emphasizes that there is no assurance that the settlement will be finalized or approved on the terms set forth above, or at all. The Company will file additional updates as appropriate once the settlement process is finalized. As disclosed previously, Allarity understands that three of its former officers received Wells Notices. The three former officers who received a Wells Notice related to this matter are no longer with the Company, nor were they at the time of receipt of the Wells Notice. While the Company has reached an agreement in principle o

View Full Filing

View this 8-K filing on SEC EDGAR